A disturbing trend is emerging in emergency departments across the United States and beyond: young people presenting with severe, uncontrollable vomiting and abdominal pain caused by chronic cannabis use. This condition, known as cannabis hyperemesis syndrome (CHS), represents a stark contradiction to the widely held belief that marijuana is harmless, particularly amongst adolescents and young adults.

Recent research has documented a staggering 10-fold increase in emergency department visits for cannabis hyperemesis syndrome amongst adolescents over just a seven-year period. This dramatic surge coincides with broader societal acceptance of cannabis use and, in many jurisdictions, legalisation of recreational marijuana. The implications for young people’s health are profound and deeply concerning.

What Is Cannabis Hyperemesis Syndrome?

Cannabis hyperemesis syndrome is a paradoxical condition that develops in some chronic, heavy cannabis users. Whilst marijuana is often promoted for its anti-nausea properties and has legitimate medical uses in chemotherapy patients, prolonged heavy use can trigger the opposite effect: severe, cyclical vomiting episodes accompanied by intense abdominal cramping.

Dr Andrew Meltzer, professor of emergency medicine at George Washington University, explains that cannabis exhibits a “biphasic reaction” where it transitions “from being an antiemetic to pro-emetic” with chronic and heavy use. This phenomenon catches many users completely off guard, as they’ve often used cannabis for years without experiencing such severe adverse effects.

One of the most distinctive features of cannabis hyperemesis syndrome is patients’ compulsive use of hot showers and baths to find relief. This unusual symptom provided early clues that CHS represents a distinct medical entity. Patients report that whilst actively in hot water, their symptoms temporarily subside, only to return once they exit the shower or bath. Some individuals have developed burns from excessively hot water in desperate attempts to alleviate their suffering.

The condition manifests in stereotypical episodes remarkably similar to cyclic vomiting syndrome, but with clear links to cannabis use. Patients present to emergency departments with severe dehydration, electrolyte imbalances, and occasionally acute kidney injury from persistent vomiting. In rare cases, deaths have been reported, though these remain uncommon.

The Science Behind Cannabis Hyperemesis Syndrome

Understanding why cannabis hyperemesis syndrome develops requires examining how chronic marijuana use affects the body’s endocannabinoid system. The human body produces its own cannabinoids (endocannabinoids) that interact with cannabinoid receptors throughout the brain and gastrointestinal tract.

When someone ingests large amounts of phytocannabinoids (plant-derived cannabinoids like THC from marijuana), it disrupts the body’s natural endocannabinoid regulation. The CB1 and CB2 receptors that normally respond to the body’s own cannabinoids become overstimulated by external sources, leading to dysregulation.

The reason hot water provides temporary relief relates to the TRPV1 receptor. This receptor responds to both heat and capsaicin (the compound that makes chilli peppers hot), which is why capsaicin cream has been explored as a potential treatment. When activated by heat, the TRPV1 receptor appears to temporarily override the signals causing nausea and vomiting.

Emerging research suggests cannabis hyperemesis syndrome may involve an immunological or allergic-type reaction. Dr Meltzer’s research has identified elevated biomarkers associated with allergies in CHS patients, including human leukocyte antigen (HLA) markers and immunoglobulin E (IgE) receptors. This has led some researchers to describe it to patients as having “developed an allergy” to cannabis after prolonged use.

This allergic-type response may explain why some patients become so sensitive that even secondhand smoke exposure can trigger symptoms. Patients report feeling nauseous and experiencing abdominal cramping simply from being in rooms where others are smoking cannabis, highlighting the severity of the body’s reaction.

Why Young People Are Particularly Vulnerable

The dramatic rise in cannabis hyperemesis syndrome amongst adolescents and young adults is especially troubling given what we know about brain development. The adolescent brain undergoes critical maturation processes that continue into the mid-twenties, particularly in regions responsible for decision-making, impulse control, and risk assessment.

Dr Meltzer’s research, published in the Annals of Emergency Medicine, surveyed 1,052 individuals with self-reported cannabis hyperemesis syndrome to identify risk factors for severity. The findings were clear: patients who began regular daily cannabis use before age 18 experienced significantly higher rates of emergency department visits and hospitalisations.

Those starting cannabis use in their early teens, sometimes using the drug five to ten times daily, face the greatest risk of developing severe CHS. The developing brain appears particularly susceptible to the dysregulation that leads to this condition, with early initiation creating a pathway to chronic heavy use and its consequences.

Beyond cannabis hyperemesis syndrome itself, early cannabis use carries additional risks to adolescent brain development. Research has linked teen marijuana use to impaired memory, reduced attention span, decreased academic performance, and increased risk of mental health disorders including psychosis and schizophrenia. Starting cannabis use at age 12 or 13, as some young people do, exposes the developing brain to substances during its most vulnerable developmental period.

The Potency Problem and Cannabis Hyperemesis Syndrome

The increasing potency of cannabis products has likely contributed to the surge in cannabis hyperemesis syndrome cases. Decades ago, marijuana typically contained 3-5% THC (tetrahydrocannabinol, the primary psychoactive compound). Today’s cannabis flower commonly contains 20-25% THC or higher, representing a four to eight-fold increase in potency.

Even more concerning are concentrated cannabis products. Edibles may contain 1,000 milligrams of THC in a single item. Vaping cartridges and dabs can contain THC concentrations approaching 90-95%. When young people consume these high-potency products regularly, they’re exposing themselves to THC doses far exceeding what previous generations encountered.

Dr Meltzer emphasises that this dramatic increase in potency means “you have people using stronger strains, you have people using it more, and you have people using it for longer periods of time. It’s not surprising that we’re starting to see some different side effects than maybe we saw 20 or 30 years ago.”

The condition itself was only described in medical literature 20-25 years ago, representing a relatively new disease entity that has emerged alongside increased cannabis potency and availability. As Dr Meltzer notes, “There are not many new diseases that we’ve encountered in the midst of our career, and this is one of them.”

Recognising Cannabis Hyperemesis Syndrome

Early recognition of cannabis hyperemesis syndrome can prevent repeated emergency department visits, unnecessary medical procedures, and serious complications. However, diagnosis can be challenging because the symptoms mimic other gastrointestinal conditions.

Patients with CHS often undergo extensive workups before receiving the correct diagnosis. They may receive multiple CT scans, endoscopies, and consultations with gastroenterologists whilst doctors rule out conditions like pancreatitis, gallbladder disease, small bowel obstruction, inflammatory bowel disease, or Crohn’s disease.

The key distinguishing features of cannabis hyperemesis syndrome include a history of chronic, heavy cannabis use (typically daily use for months or years), cyclical episodes of severe vomiting and abdominal pain, temporary relief from hot showers or baths, and resolution of symptoms with complete cannabis cessation.

Many patients initially resist the idea that marijuana could be causing their symptoms. They’ve often used cannabis for years without problems and may rely on it for anxiety, sleep, or other perceived benefits. This resistance delays diagnosis and prolongs suffering, as patients continue using the substance causing their condition.

Dr Meltzer notes that awareness has improved significantly: “When I tell a patient that cannabis might be causing their symptoms, it’s pretty rare now that they haven’t heard it from at least one person before, or even a family member, or thought about it before that maybe cannabis is possibly a cause.” This growing recognition represents progress, though many young people still remain unaware of the risk.

Treatment Challenges for Cannabis Hyperemesis Syndrome

Managing cannabis hyperemesis syndrome presents multiple challenges. In the acute setting, when patients arrive at emergency departments severely ill, treatment focuses on controlling symptoms and preventing complications from dehydration.

Interestingly, standard anti-nausea medications often prove ineffective for CHS. Ondansetron (Zofran), commonly used for nausea and vomiting, typically provides little relief. Instead, antidopaminergic medications like haloperidol and droperidol work much better. This difference relates to the specific receptors affected by chronic cannabis use and provides another clue to CHS’s underlying mechanisms.

However, acute symptom management represents only part of the challenge. The only definitive treatment for cannabis hyperemesis syndrome is complete and permanent cessation of all cannabis use. Even small exposures can trigger symptom recurrence, meaning patients cannot simply reduce their consumption or switch to different cannabis products.

This creates a significant hurdle, as many patients with CHS meet criteria for cannabis use disorder. They’ve developed physical and psychological dependence on marijuana, making cessation extremely difficult. Cannabis withdrawal, whilst not life-threatening like alcohol or benzodiazepine withdrawal, can cause irritability, insomnia, decreased appetite, anxiety, and restlessness that make quitting challenging.

Currently, no medications are approved specifically for treating cannabis use disorder or addiction. Researchers are exploring various approaches, including partial cannabinoid receptor antagonists and N-acetylcysteine, but none have yet proven definitively effective. This leaves behavioural interventions as the primary treatment approach.

The Path to Recovery

Helping young people overcome cannabis use disorder and recover from cannabis hyperemesis syndrome requires comprehensive, sustained support. The first critical step involves helping patients recognise and accept that cannabis is causing their symptoms.

Dr Meltzer emphasises the importance of this recognition: “One of the first things you do is just try to get people to recognise what’s causing this. Patients might be really resistant to thinking that marijuana is the cause of their symptoms.” Multiple healthcare providers may need to deliver this message before it’s fully accepted.

Once patients acknowledge the connection, developing a cessation plan becomes essential. For individuals who have used cannabis 5-10 times daily for years, this represents not just breaking an addiction but fundamentally changing their lifestyle. Cannabis use may be deeply integrated into their social relationships, daily routines, and coping mechanisms.

Motivational interviewing and cognitive behavioural therapy represent evidence-based approaches for addressing cannabis use disorder. These therapeutic modalities help patients identify triggers, develop healthier coping strategies, and build motivation for change. However, access to these services remains limited in many areas, particularly for adolescents and young adults.

Family involvement can significantly enhance treatment success. Parents and other family members can provide crucial support whilst helping young people restructure their lives around healthier activities and relationships. Family therapy may address relationship patterns that contribute to substance use whilst strengthening the support systems essential for recovery.

The challenge lies in preventing recidivism. Even after successful initial cessation, many patients return to cannabis use and subsequently return to emergency departments with recurrent CHS episodes. Dr Meltzer acknowledges, “What we really haven’t been able to do is help them come up with a really good strategy in the long term and decrease the recidivism of cannabis use and repeat ED visits.”

The Economic and Healthcare Burden

Whilst precise economic data remains limited due to challenges in tracking cannabis hyperemesis syndrome cases, the healthcare burden is clearly substantial and growing. Patients with CHS often visit emergency departments multiple times before receiving correct diagnosis. Each visit may involve expensive imaging studies like CT scans, laboratory work, intravenous fluids, medications, and sometimes hospitalisation.

The lack of a specific ICD-10 diagnostic code for cannabis hyperemesis syndrome complicates efforts to track the condition’s true prevalence and economic impact. Researchers must typically identify cases by looking for combinations of chronic cannabis use codes and gastrointestinal symptom codes, an imperfect methodology that likely underestimates true case numbers.

Beyond direct healthcare costs, CHS imposes indirect economic burdens through missed work and school, reduced productivity, and diminished quality of life. Young people with severe CHS may struggle to maintain employment or academic progress, affecting their long-term economic prospects.

Dr Meltzer’s research group is conducting prospective observational studies following patients for months to years after emergency department diagnosis to better understand the full scope of CHS’s impact. This research will help quantify both the healthcare utilisation and broader economic consequences of this growing condition.

Prevention: The Most Effective Approach to Cannabis Hyperemesis Syndrome

Given the challenges in treating cannabis hyperemesis syndrome once it develops, prevention represents the most effective strategy. This requires honest, evidence-based education about cannabis risks, particularly for adolescents and young adults.

Current public health messaging about cannabis often emphasises its relative safety compared to alcohol or opioids, its medical applications, and arguments for legalisation. Whilst these discussions have merit in appropriate contexts, they’ve contributed to widespread perceptions amongst young people that marijuana is essentially harmless.

Dr Meltzer observes: “We’ve told people for a long time that there’s this medicinal use of cannabis and that it’s very safe. We generally agree that it’s obviously safer than alcohol or opiates. The question is, what happens with long-term use and chronic use and using high volumes or high potency use on a daily basis? Especially starting in the adolescent ages, this is what we really don’t know.”

The messaging young people receive must acknowledge that whilst cannabis may be legal in some jurisdictions and has legitimate medical uses in specific contexts, chronic heavy use carries real risks. Cannabis hyperemesis syndrome represents just one of multiple potential adverse effects, alongside impacts on brain development, mental health, academic performance, and driving safety.

Educational efforts should target both young people and their parents. Many parents who used marijuana in their youth assume today’s cannabis is essentially the same, unaware of dramatic potency increases and new consumption methods. Parents need accurate information to have meaningful conversations with their children about cannabis risks.

Schools, healthcare providers, and community organisations all have roles to play in cannabis education. Paediatricians and family doctors should routinely screen adolescents for substance use, including cannabis, and provide counselling about risks. This early intervention, before heavy use patterns develop, offers the best opportunity to prevent conditions like cannabis hyperemesis syndrome.

The Societal Context

The surge in cannabis hyperemesis syndrome amongst young people doesn’t occur in isolation. It reflects broader societal changes regarding cannabis acceptance, availability, and use patterns.

Dr Meltzer notes that cannabis is now the most commonly used substance in the United States, with more daily or near-daily users than alcohol. Cannabis shops appear “on every corner in most cities,” making the drug remarkably accessible. Meanwhile, mental health care and even primary care can be difficult for young people to access, creating a concerning imbalance.

Legalisation has undoubtedly contributed to increased use, though the relationship is complex. The study documenting the 10-fold increase in adolescent CHS cases found rises in both states with recreational legalisation and those without, though increases were somewhat greater in legalised states.

More significant than legal status may be the overall cultural normalisation of cannabis use. When young people see marijuana shops next to coffee shops, when they hear about cannabis’s medical benefits, when they observe adults using recreationally without apparent consequences, they naturally conclude it must be safe.

This normalisation has occurred faster than research into long-term effects, particularly in adolescents. The current generation of young cannabis users represents an unintended experiment in the effects of widespread, high-potency marijuana use starting in adolescence. Cannabis hyperemesis syndrome may be just one of multiple adverse outcomes we’re beginning to observe.

Moving Forward

Addressing cannabis hyperemesis syndrome in young people requires comprehensive action. Healthcare providers need better diagnostic tools, whilst research must continue exploring effective interventions for cannabis use disorder.

Public health messaging must ensure young people understand that legal doesn’t mean safe. As Dr Meltzer emphasises: “Just because it’s now legal and legal for recreational use does not mean that it’s necessarily safe. As we know in medicine, we often say, ‘The dose makes the toxin.’ When you’re taking anything at high doses, you’re going to see side effects.”

Parents, educators, and community members must remain vigilant about adolescent cannabis use. Starting marijuana at ages 12, 13, or 14, using it multiple times daily, and continuing for years creates conditions for developing CHS and numerous other adverse effects.

The 10-fold increase in adolescent emergency department visits for cannabis hyperemesis syndrome over just seven years represents a preventable public health crisis. Every case in a teenager highlights the urgent need for better education, prevention, and early intervention to protect young people from this painful condition and the dangers of chronic, heavy cannabis use during critical developmental years.

Source: Medscape